Study guide

12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage

Key Takeaways Explain This Topic AI

Colonization and infection of burn wounds follow a predictable chronological shift: Gram-positive organisms (S. aureus, S. pyogenes) dominate Days 1–5; Gram-negative bacilli (Pseudomonas, Acinetobacter, Klebsiella) dominate Days 5–14; and multidrug-resistant (MDR) bacteria and opportunistic fungi (Candida, Aspergillus, Mucorales) emerge after 14 days or prolonged ICU hospitalization.

Pseudomonas aeruginosa produces potent virulence factors (elastase, exotoxin A, pyocyanin), creating blue-green fluorescent wound exudate with a characteristic sweet/fruity odor, and exhibits vasculotropism that triggers ischemic tissue necrosis and ecthyma gangrenosum.

Routine prophylactic systemic antibiotics are strictly contraindicated in burn care because they do not penetrate avascular eschar, fail to prevent wound colonization, and rapidly select for pan-drug resistant bacteria and lethal invasive fungal superinfections.

Invasive mold infections (Aspergillus, Mucorales/Zygomycetes) carry catastrophic mortality (>50–70%) in massive burns, demanding immediate systemic antifungal therapy (liposomal amphotericin B) paired with urgent radical surgical debridement of infected tissue.

Burn hypermetabolism significantly alters antimicrobial pharmacokinetics via an expanded Volume of Distribution (Vd) and Augmented Renal Clearance (ARC; CrCl >130–200 mL/min), necessitating higher loading doses, shortened dosing intervals, extended/continuous beta-lactam infusions, and rigorous therapeutic drug monitoring (TDM).

Last updated: August 2026

12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage

Core Knowledge: The microbiology of burn wounds is dynamic, evolving through well-defined chronological phases over the patient's hospital course. Successful antimicrobial management requires an understanding of pathogen-specific virulence factors, strict adherence to antimicrobial stewardship (avoiding non-directed prophylactic systemic antibiotics), and expert navigation of the altered pharmacokinetic/pharmacodynamic (PK/PD) environment driven by burn hypermetabolism and augmented renal clearance.

1. Chronological Evolution of Burn Microbial Flora

Immediately following thermal injury, the burn wound surface is sterile due to thermal denaturation. However, microorganisms rapidly colonize the avascular eschar from endogenous skin appendages, the patient's gastrointestinal tract, and the external hospital environment. CHRONOLOGICAL EVOLUTION OF BURN MICROFLORA

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ DAYS 1 – 5: EARLY PHASE (Gram-Positive Predominance) │
  • │ • Source: Deep skin appendages, hair follicles, sebaceous glands │
  • │ • Pathogens: Staphylococcus aureus, Streptococcus pyogenes (GAS) │
  • │ • Clinical Course: Cellulitis, localized purulence, erythema │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ DAYS 5 – 14: INTERMEDIATE PHASE (Gram-Negative Bacilli Shift) │
  • │ • Source: Endogenous gut translocation, environmental BICU vectors │
  • │ • Pathogens: Pseudomonas aeruginosa, Acinetobacter baumannii, │
  • │ Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis │
  • │ • Clinical Course: Rapid eschar liquefaction, vasculotropic invasion │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ > 14 DAYS / PROLONGED ICU: LATE PHASE (MDR & Fungal Emergence) │
  • │ • Source: Broad-spectrum antibiotic selective pressure, long-term lines │
  • │ • Pathogens: Multi-Drug Resistant (MDR) Gram-negatives (CRAB, CRE), │
  • │ Vancomycin-Resistant Enterococcus (VRE), Opportunistic Fungi: │
  • │ Candida spp. (C. albicans, C. glabrata), Molds (Aspergillus, Mucor) │
  • │ • Clinical Course: Deep angioinvasive necrosis, hematogenous seeding │
  • └────────────────────────────────────────────────────────────────────────┘
  • 2. High-Yield Burn Pathogens and Clinical Characteristics

Pathogen Class & Species Key Virulence Mechanisms Distinctive Clinical Hallmarks Empiric & Targeted Antimicrobial Agents

Pseudomonas aeruginosa (Gram-Negative Bacillus) Exotoxin A (inhibits protein synthesis via EF-2 ADP-ribosylation), elastase, biofilm/alginate, pyocyanin/pyoverdine pigments. Vasculotropic (invades perivascular adventitia). Blue-green fluorescent exudate on dressings; sweet, fruity/grape-like odor; rapid eschar dissolution; ecthyma gangrenosum (erythematous bullae progressing to black necrotic ulcers). Cefepime, Piperacillin-tazobactam, Meropenem, Ceftolozane-tazobactam, Aminoglycosides (Tobramycin), Inhaled Colistin.

Methicillin-Resistant S. aureus (MRSA) (Gram-Positive Coccus) PBP2a \text{PBP2a} PBP2a alteration (mecA gene), Panton-Valentine leukocidin (PVL), alpha-hemolysin, toxic shock syndrome toxin-1 (TSST-1). Thick golden-yellow purulence; rapidly progressing necrotizing pneumonia in inhalation injury; graft lysis and loss of newly placed autografts. Vancomycin (target AUC/MIC 400–600), Linezolid, Daptomycin (not for pneumonia), Ceftaroline.

Acinetobacter baumannii (MDR Gram-Negative Bacillus) Extreme desiccation resistance on bedrails and surfaces; biofilm formation; OXA-carbapenemases and metallo- β \beta β -lactamases (CRAB). Rapid colonizer in BICUs; white-gray mucoid exudate; highly transmissible nosocomial outbreaks; pan-drug resistance. Ampicillin-sulbactam (high-dose), Meropenem-vaborbactam, Cefiderocol, Polymyxin B / Colistin, Tigecycline.

Candida albicans / C. glabrata / C. auris (Opportunistic Yeast) Adhesins, phenotypic switching, biofilm formation on central lines and catheters; translocation across ischemic gut. White satellite pustules; sub-eschar creamy exudate; sudden visual field defects (Candida endophthalmitis); refractory fever on broad-spectrum antibiotics. Echinocandins (Caspofungin, Micafungin, Anidulafungin), Fluconazole (for susceptible C. albicans), Liposomal Amphotericin B.

Aspergillus & Mucorales (Invasive Filamentous Fungi / Molds) Hyphal angioinvasion causing vascular thrombosis, ischemic infarction, and tissue destruction; thermotolerant spores. Dark brown/black leathery eschar discoloration ; sudden depth conversion to full-thickness; black necrotic advancing edge; lack of bleeding during excision. Emergency surgical re-excision + Liposomal Amphotericin B (5–10 mg/kg/day), Isavuconazole, Voriconazole (Aspergillus).

3. Antimicrobial Stewardship in the Burn Center

Burn patients are among the highest consumers of antimicrobials in the hospital setting. Without strict stewardship, the emergence of pan-drug resistant bacteria and opportunistic fungal superinfections becomes inevitable. TENETS OF BURN ANTIMICROBIAL STEWARDSHIP

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ 1. NO PROPHYLACTIC SYSTEMIC ANTIBIOTICS: Prophylactic IV antibiotics │
  • │ do NOT prevent wound infection, do not reach avascular eschar, and │
  • │ select for lethal MDR pathogens and Candida/Aspergillus. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 2. CULTURE BEFORE ANTIMICROBIALS: Always obtain blood (2 sets), sputum,│
  • │ urine, and quantitative wound biopsy PRIOR to initiating antibiotics│
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 3. TARGETED EMPIRIC COVERAGE: Base initial empiric therapy on unit- │
  • │ specific antibiograms and known patient surveillance colonization. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 4. TIMELY DE-ESCALATION: Re-evaluate at 48–72 hours; narrow spectrum │
  • │ or discontinue agents based on definitive microbiological cultures. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 5. FINITE TREATMENT DURATIONS: Treat documented infections for 5–7 days │
  • │ (except bacteremia/endocarditis); stop empiric therapy if cultures │
  • │ are negative and clinical sepsis triggers resolve. │
  • └────────────────────────────────────────────────────────────────────────┘
  • 4. Pharmacokinetics and Pharmacodynamics (PK/PD) in Burn Hypermetabolism

Standard drug dosing regimens published for general medical patients frequently result in subtherapeutic antimicrobial concentrations in burn patients, leading to clinical treatment failure and the emergence of resistant strains. ALTERED PK/PD MECHANISMS IN MAJOR BURNS

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ 1. MASSIVELY EXPANDED VOLUME OF DISTRIBUTION (Vd) │
  • │ • Pathophysiology: Endothelial permeability, massive fluid resuscitation│
  • │ (crystalloids), and tissue edema dramatically expand extracellular │
  • │ fluid volume. │
  • │ • Impact: Hydrophilic drugs (Beta-lactams, Aminoglycosides, Vancomycin)│
  • │ are diluted in blood, requiring LARGER INITIAL LOADING DOSES. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 2. AUGMENTED RENAL CLEARANCE (ARC) │
  • │ • Pathophysiology: Massive catecholaminergic hyperdynamic state drives │
  • │ cardiac output to 10–18 L/min, producing renal hyperperfusion and │
  • │ glomerular hyperfiltration (Creatinine Clearance > 130–250 mL/min). │
  • │ • Impact: Hydrophilic antibiotics are rapidly eliminated by kidneys, │
  • │ requiring HIGHER MAINTENANCE DOSES & SHORTER DOSING INTERVALS. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 3. HYPOALBUMINEMIA & ALTERED PROTEIN BINDING │
  • │ • Pathophysiology: Exudative protein loss and liver synthesis shifts │
  • │ reduce serum albumin (<2.0 g/dL), while alpha-1 acid glycoprotein │
  • │ surges as an acute-phase reactant. │
  • │ • Impact: Highly protein-bound drugs (Ceftriaxone, Daptomycin) exhibit │
  • │ increased free fraction, accelerating renal clearance. │
  • └────────────────────────────────────────────────────────────────────────┘

Clinical Strategies for Burn PK/PD Optimization:

Extended / Continuous Beta-Lactam Infusions: Beta-lactams are time-dependent antimicrobials ( T > MIC T > \text{MIC} T > MIC ). In patients with Augmented Renal Clearance, standard intermittent boluses fail to maintain drug concentrations above the minimum inhibitory concentration (MIC). Administering piperacillin-tazobactam or cefepime as 3- to 4-hour extended infusions or 24-hour continuous infusions maximizes bactericidal efficacy.

Therapeutic Drug Monitoring (TDM): Mandatory for vancomycin (target AUC/MIC ratio 400 to 600 , or trough 15 – 20 μ g/mL 15\text{--}20\;\mu\text{g/mL} 15 – 20 μ g/mL ) and aminoglycosides (high-dose once-daily tobramycin with peak monitoring to ensure C max ⁡ / MIC ≥ 10 C_{\max}/\text{MIC} \ge 10 C m a x ​ / MIC ≥ 10 ).